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Abstract. Finding optimal policies to reduce the morbidity and mortality of
the ongoing pandemic is a top public health priority. Using a compartmental
model with age structure and vaccination status, we examined the effect of
age specific scheduling of vaccination during a pandemic influenza outbreak,
when there is a race between the vaccination campaign and the dynamics of the
pandemic. Our results agree with some recent studies on that age specificity is
paramount to vaccination planning. However, little is known about the effec-
tiveness of such control measures when they are applied during the outbreak.
Comparing five possible strategies, we found that age specific scheduling can
have a huge impact on the outcome of the epidemic. For the best scheme, the
attack rates were up to 10% lower than for other strategies. We demonstrate
the importance of early start of the vaccination campaign, since ten days de-
lay may increase the attack rate by up to 6%. Taking into account the delay
between developing immunity and vaccination is a key factor in evaluating the
impact of vaccination campaigns. We provide a general framework which will
be useful for the next pandemic waves as well.
Keywords: influenza outbreak, epidemiological model, age specific trans-
mission, vaccination strategy, A(H1N1)v
1. Introduction
Developing strategies for mitigating the severity of the influenza epidemics is a top
public health priority. As soon as vaccine became available, vaccination campaigns
started in several countries as a primary mitigation strategy against the first wave of
the 2009 A(H1N1) pandemic. Mathematical models are powerful tools for evaluat-
ing intervention strategies and quantifying the potential benefits of different options
(Moghadas et al. 2009). We use a compartmental system with five age groups rep-
resenting the European population, that incorporates transmission dynamics based
on social contact profiles from survey data (Mossong et al. 2008) and vaccination
status. Vaccination has not only direct benefit to the individual, but also reduces
the risk for those who have not been vaccinated. Giving priority to groups who are
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the most responsible for spreading the infection can be a benefit to other groups as
well.
US officials have announced that over several months, vaccines for up to 20% of the
population per month could be delivered (Robinson 2009), although later they were
facing difficulties with providing supplies. Hungary has a similar maximal produc-
tion capacity in the range of up to 5% of the population per week (Falus 2009), thus
here we targeted a 60% vaccine coverage by the end of a three months campaign.
Recent studies revealed the importance of age specific intervention strategies, and
discussed how to distribute vaccines among age groups, assuming preseasonal vac-
cination (Longini & Halloran 2005; Medlock & Galvani 2009). Here we focus on a
completely different aspect: how to prioritize the different groups in the timing of
the schedule. Therefore for the purposes of this study, in the baseline scenario we
assume that a 60% total coverage is reached within each age group by the end of
the vaccination campaign, and we compare different strategies for the order and
the timing of vaccinating different age groups during the campaign. Furthermore, a
range of different scenarios are considered in the sensitivity analysis. The relatively
low basic reproduction number of influenza (see Chowell et al. 2007 and Chowell
et al. 2006 for estimations of the reproduction numbers for seasonal and pandemic
influenza in temperate countries) implies that effective measures such as vaccination
before the pandemic wave could be important, however little is known about the
effectiveness of such measures during a pandemic wave.
As it could be observed all around the world, vaccination campaigns and A(H1N1)v
outbreaks overlapped in time, thus the preseasonal vaccination assumption does not
hold. There is an ongoing race between the vaccination campaign and the dynamics
of the outbreak, hence it is necessary to implement a dynamic modelling of the
interplay of the vaccination and the influenza transmission.
Age structured models are necessary for multiple reasons: various age groups have
very different contact profiles thus playing different roles in transmitting the dis-
ease. Furthermore, age specific susceptibility, infectiousness, vaccine efficacy and
mortality patterns are also important issues. We developed a compartmental model
to track five age groups. We incorporated the fact that it takes about two weeks to
develop antibodies and acquire immunity after vaccination, and during this inter-
mediate period an individual might contract the disease (Nichol 1998). This time
delay is shown to be a significant factor during the outbreak. To our knowledge this
is the first modelling study which reckons with that.
Here we evaluate vaccination strategies for two outcome measures: overall attack
rate and total deaths estimated from recent mortality data of the novel A(H1N1)v
pandemic (Donaldson et al. 2009 ). Though there are several other possible inter-
ventions (antiviral treatment, social distancing, school closures etc., see Alexander
et al. 2007, 2009 ; Ferguson et al. 2006; Merler et al. 2009; Moghadas et al. 2008,
2009; Gojovic et al. 2009) to mitigate the burden of the outbreak, here we focus
only on vaccination. The effect of other control measures can be taken into account
in a simplified way by lowering the reproduction number. To show the robustness of
our results, a sensitivity analysis was performed with respect to several key model
parameters, such as the basic reproduction number, vaccine efficacy, epidemiologic
characteristics of the virus, moreover the duration and the intensity of the vaccina-
tion campaign.
In the following, we detail the model structure, discuss our results and their epidemi-
ological implications, and place them in the context of the ongoing battle against
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the nascent A(H1N1)v pandemic. Our aim was to develop a model that can be
applied to explore the effect of alternative vaccination strategies, and this model
can also be used for predicting the future incidence of cases in the next wave of
pandemic influenza.
2. The model
Our model is a compartmental differential system, based on the classical SEIR
(Susceptible, Exposed, Infective, Recovered) model. We have incorporated three
features to develop a more realistic model:
i) we introduced age structure with five age groups, where the contacts between age
groups are derived from the European survey Mossong et al. 2008,
ii) we account for the fact that it takes up to 14 days after vaccination to produce
sufficient amount of antibodies to provide immunity (CDC 2009, Nichol 1998),
iii) we did not assume vaccination before the outbreak, because we want to model
the interplay between the dynamics of the epidemics and the vaccination campaign.
It is assumed that the transmission of infection occurs through close contacts be-
tween susceptibles and infected individuals, where for simplicity, mass action inci-
dence is used (Alexander et al. 2008, 2009; Arino et al. 2006). Exposed individuals
in the class E cannot transmit the disease in the latent period, during which viral
titres increase to detectable and transmissible levels (Baccam et al. 2006). Since the
latent period is relatively short, we neglected the small probability of someone re-
ceiving the vaccine while being in the class E. We assume further that infected and
recovered individuals will not be vaccinated, therefore vaccination is administered
only for individuals in the S class until we reach the targeted 60% coverage on the
population level. If the pool of susceptibles depleted before reaching that coverage,
we stopped vaccination in the simulations. However, contacts of cases may have al-
ready been infected by the time that vaccine is taken up, because high proportion of
infection is not laboratory confirmed, and also asymptomatic or atypical infections
can also occur. The magnitude of such limitation is less of a problem when consider-
ing the first epidemic wave of pandemic influenza than for the second or third wave.
The model tracks 5 age groups, distributed as the 2005 European Union population
(Eurostat 2006). We considered the case when a single dose is sufficient to induce
immunity. A single dose is recommended for the Hungarian vaccine (Johansen et
al. 2009; Vajo et al. 2009), and according to the most up-to-date recommendation
of the European Medicines Agency that can be sufficient for other vaccines as well,
see also (Nishiura & Iwata 2009; Greenberg et al. 2009). The five age groups we
considered are 0-9, 10-19, 20-39, 40-64 and 65+ years old. In the model equations we
use the upper index i = 1, ..., 5 to denote the corresponding age group, respectively.
Based on the most recent serological data (Miller et al. 2010), we assumed no pre-
existing immunity in the first four age groups, and 20% reduction in susceptibility
in the elder age group.
Vaccinated individuals move into the classW for an intermediate period, during that
infection is still possible. After 14 days they become immune with probability q, and
move into the RW class, or if the vaccine was ineffective, then they move into SV ,
meaning that they are still susceptible to the disease despite having been vaccinated.
Such individuals will not receive the vaccine again, but can come into contact with
infectious individuals and contract the disease. It is assumed in the baseline scenario
that the same epidemiological parameters apply to these individuals as to the non-
vaccinated, i.e. µEV = µE and µIV = µI , except that we assumed a reduction of
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infectiousness for unsuccessfully vaccinated persons (see Table 1). This factor δ is
set to be 0.75 in the baseline scenario, but other possibilities for the parameters of
unsuccessfully vaccinated individuals are also discussed in the sensitivity analysis.
The epidemiological parameters, such as the length of incubation and infectious
periods, vaccine efficacy, transmission rates etc. are taken from the literature and
discussed in detail in Section 3.
The transmission diagram of our model is presented in Figure 1, without the age
structure.
Thus, altogether we have 50 compartments and the following non-autonomous sys-
tem of 50 differential equations
S˙i = −Siλi − V i S˙iV = (1− qi)µWW
i − SiV λ
i
E˙i = (Si +W i)λi − µiEE
i E˙iV = S
i
V λ
i − µiEV E
i
V
I˙i = µiEE
i − µiII
i I˙iV = µ
i
EV
EiV − µ
i
IV
IiV
R˙i = µiII
i R˙iV = µ
i
IV
IiV
W˙ i = V i −W iλi − µWW
i R˙iW = qiµWW
i,
where the force of infection is given by
λi =
5∑
j=1
(βj,i(I
j + δIjV ))
and the upper index i = 1, .., 5 represents the corresponding age group. Here V i =
V i(t) are the prescribed piecewise constant vaccination rate functions determined by
the specific strategy. In our equations we ignored mortality, since even a 40% attack
rate and 0.05% case fatality rate cause very minor changes in the demographic
scale, and the number of disease induced deaths can be derived simply from the
attack rate and the case fatality ratio. Nevertheless, the age specific mortality is an
important issue, and such information can be obtained from the age specific attack
rates calculated by the model and the mortality patterns when they are available,
see Section 4 and 5. We start the model at t = 0, with time measured in days,
introducing a small number of infectives into the population. The time T refers to
the delay in start of the vaccination campaign, thus V i(t) = 0 for any t < T , and
in a case of a three months campaign, V i(t) = 0 for t > T + 90 as well.
3. Parameters
The epidemiological parameters are summarized in Table 1. So far there are no
precise clinical estimates of the basic model parameters µE and µI defining the in-
verse average exposed and infectious time durations, hence we used plausible values
from the range estimated in Balcan et al. 2009 . We used the age distribution of
the European Union (Eurostat 2006) for our simulations. For vaccine efficacy we
used the same parameters as in Medlock & Galvani 2009, obtained from Basta et
al. 2008. In the sensitivity analysis we considered various values for the reduction
of infectiousness δ and vaccine efficacy against infection qi. The value of µW , rep-
resenting the inverse time duration needed to develop antibodies to gain immunity,
is the same as US CDC 2009 uses, being in accordance with Nichol 1998.
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Figure 1. Transmission diagram without age structure. Here W
is the compartment of those who have been recently vaccinated,
RW who have already acquired immunity after vaccination, and
the subscript V denotes the classes of unsuccessfully vaccinated
people.
parameter notation value (range) source
latent period 1/µE 1.25 days Balcan et al. 2009
infectious period 1/µI 3 days Balcan et al. 2009
vaccine efficacy for 0-65 yrs old qi, i = 1..4 0.8 (0.7-0.9) Basta et al. 2008
vaccine efficacy for 65+ yrs old q5 0.6 (0.5-0.7) Basta et al. 2008
transmission rates βi,j see 3.2 Mossong et al. 2008
time to develop antibodies 1/µW 14 days Nichol 1998
reduction in infectiousness δ 0.75 (0.5-1)
vaccination coverage 60%(30%-80%)
basic reproduction number R0 1.4 (1.2-1.8) Truite et al. 2009
Table 1. Description of the model parameters
3.1. Baseline scenario. The severity of the influenza outbreak and the initial
rate of increase depends on the basic reproduction number R0, which is among
the most urgently estimated quantities in a pandemic situation, and defined as the
average number of secondary infectious cases caused by an infected individual in
a population consisting of susceptibles only (Diekmann et al. 2010; Heffernan et
al. 2005). In the baseline scenario we assumed that the basic reproduction number
R0 is 1.4. This value seems to be reasonable (Truite et al. 2009) and similar to
mean estimates of seasonal infuenza in temperate countries , however, we considered
milder and more severe cases (R0 = 1.2, R0 = 1.6, R0 = 1.8) as well. We run
computer simulations for a population of N = 100000. Due to the special form of
the equations, the results are scalable and the attack rates (defined as the fraction
of susceptibles who do not contract the disease during the course of the outbreak)
remain the same for populations of any size. In the baseline scenario, after the start
of the vaccination campaign at time T , vaccine is administered to 0.667% of the
population per day, thus reaching a coverage of 60% at the end of the campaign at
time T +90. This is an intensive, but realizable vaccination plan (Falus 2009). The
distribution of these vaccines among the age groups on any given day is determined
by the specific strategy (see Section 4). Based on European Union statistics Eurostat
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2006, we use the following age distribution per 100 000 citizens:
N1 N2 N3 N4 N5
10500 12000 28500 32500 16500
,
where N i is the total number of individuals in age group i, and N =
∑
5
i=1N
i.
3.2. The contact matrix and the basic reproduction numbers. There are
practical reasons for using five age groups besides for simplicity: we think that tar-
geting smaller groups is not feasible in a real situation, and we can not expect to
have vaccination data with such details. Also, in view of the data in Mossong et
al. 2008, the population can be divided into these five age groups with more or
less similar contact profiles within these larger groups, which are then easier to be
targeted. Following Medlock & Galvani 2009, we used the European survey data
Mossong et al. 2008 to estimate the transmission rates between age groups. That
survey dealt with 17 age groups (0,1-4,5-9,10-14,..,70-74 and 75+) in 8 European
countries. Since we work with different age groups, after averaging the European
contact matrices from the 8 countries weighted by their population size, we calcu-
lated a 5× 5 contact matrix C¯ = (c¯i,j), using weighted averaging based on EU age
distribution (Eurostat 2006) to combine smaller age groups into the larger ones.
Since contacts are assumed to be mutual, following Medlock & Galvani 2009, we
performed a symmetrization procedure to ensure that the total number of contacts
between two age groups are consistent: we set
ci,j =
c¯i,jN
i + c¯j,iN
j
2N i
.
Eventually, we obtained the contact matrix
C =


5, 3580 1, 0865 3, 0404 2, 4847 0, 8150
0, 9507 10, 2827 2, 8148 3, 6215 0, 7752
1, 1201 1, 1852 6, 5220 4, 1938 0, 9016
0, 8027 1, 3372 3, 6776 5, 2632 1, 3977
0, 5187 0, 5638 1, 5573 2, 7531 2, 0742


,
where the elements ci,j represent the number of contacts an individual in age group
i has with individuals in age group j, and satisfy ci,jN i = cj,iN j .
Age specific contact rates can be converted to the age specific transmission rates βi,j
as follows. An infected individual in age group i has ci,j contacts with individuals in
age group j, at some time t a fraction Sj(t)/N j of those contacts are with suscep-
tibles, SjV (t)/N
j with vaccinated susceptibles and W j(t)/N j with recent vaccinees.
Thus, we obtain that the rates of infections in age group j by individuals in age
group i is given by
βci,j
Sj(t)
N j
Ii(t), βci,j
δSjV (t)
N j
Ii(t), βci,j
W j(t)
N j
Ii(t),
where β is a transmission parameter, which involves the normalization of the con-
tacts to unit time and the infectiousness of the virus. By defining βi,j = βci,j/N j ,
we obtain the model equations and force of infections described in Section 2. Using
the transmission rates we can construct the next generation matrix N (see Diek-
mann et al. 2010), and then fit β numerically to ensure that the basic reproduction
number, which is the dominant eigenvalue of the next generation matrix, is equal
to 1.4.
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Since in the early phase of the pandemic Sj
0
≈ ̺jN j (where ̺j = 1 for j = 1, 2, 3, 4
and ̺5 = 0.8), the number of infections generated in age group j by an infected indi-
vidual from age group j is given by βi,jS
j
0
/µI . The elements of the next generation
matrix are given by this formula, i.e.
N = (ni,j) =
(βi,jSj0
µI
)
i,j
=
(β̺jci,j
µI
)
i,j
,
thus they can be obtained from the elements of the contact matrix.
By standard numerical procedure we find that if β = 0.0334, then the dominant
eigenvalue of N , which is the basic reproduction number R0, equals to 1.4, thus in
the baseline scenario we use this β value.
Note that in this scenario n2,2 > 1, which means that there is a self sustaining
outbreak in the age group of 10-19 years old individuals.
4. Strategies, simulations and results
We simulate, evaluate and compare five possible strategies for the vaccination sched-
ule. In each of the strategies, vaccine is administered to about 0.667% of the popu-
lation daily and a 60% vaccination coverage is achieved by the end of the campaign
in every age groups. Each strategy determines the piecewise constant vaccination
functions V i(t) straightforward. The overall attack rates and the final size of the
epidemic are estimated from taking the values of the non-infected classes after the
pandemic wave, at t = 250.
The case fatality ratio is yet to be determined for many countries, however estimated
rates are coming down for industrialised countries to as low as 0.02% (ECDC 2009,
Presanis et al. 2009; meaning that one in five thousand cases has a fatal outcome).
Most recent risk assessments suggest that in European countries the overall fa-
tality rate may be less or similar to a moderate influenza season. However, age
specific rates are expected to show a very different picture, with higher mortality
in younger age-groups. Here we used the recently published data (Donaldson et al.
2009, Vaillant et. al 2009), and calculated with the mortality rate 20:12:30:60:80 fa-
tal outcomes per 100 000 cases in the five age groups to compare the five strategies,
but other patterns are also discussed in the sensitivity analysis.
4.1. The five strategies. Here we describe the five strategies we compare. For each
strategy, 60% overall vaccination coverage is reached by the end of the campaign in
the baseline scenario.
A - Conventional strategy
This strategy consists of three phases and we constructed it to resemble the official
strategy of Hungarian health authorities. Similar strategies have been proposed for
many other countries.
Phase 1 : 42 days, vaccination of high risk groups, elder people, emergency and
health care personnel, workers of critical infrastructure facilities. According to the
age specific breakdown (which is described in Section 3.1), 2000, 16000, 10000 people
are being vaccinated in age groups 0-19, 20-64, 65+, respectively.
Phase 2 : Vaccination campaign in schools for 18 days, 12000 children of age ≤ 19
years old.
Phase 3 : In the last 30 days, vaccination is given to the general population such
that we achieve the 60% coverage in each group by the end of this phase.
B - Uniform strategy
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This is the universal vaccination strategy, when there are no prioritized age groups,
so we assume that vaccination is completely random and 0.667% of each age group
is vaccinated daily, throughout the 90 days.
C - Elderly first strategy
Phased vaccination of elder people (age ≥ 65 years old) first up to 60 % coverage
before vaccine is delivered to the other part of the population (age ≤ 64 years). This
two-phase strategy is similar to plans usually implemented against seasonal flu.
Phase 1 : 15 days, 65+ years old
Phase 2 : 75 days, 0-64 years old
D - Children first strategy
Phased vaccination of children (age ≤ 18 years old) first up to 70 % coverage before
vaccine is delivered to adults was studied in Yang et al. 2009. The only difference
here in the D strategy is that coverage goes up to only 60%, and our prioritized age
group is the 0-19 years old. Specifically:
Phase 1 : 20 days, 0-19 years old
Phase 2 : 70 days 20+ years old
E - By contacts strategy
Here we take advantage of the full contact structure of our five age groups, and
vaccinate them in five phases, according to the decreasing order of their total contact
numbers.
Phase 1 : 10-19 years old, 11 days
Phase 2 : 20-39 years old, 26 days
Phase 3 : 0-9 years old, 10 days
Phase 4 : 40-64 years old, 29 days
Phase 5 : 65+ years old, 15 days
4.2. Main results. We have evaluated and compared the above described five
strategies for various delays in start of the vaccination. Increasing population level
immunity may slow down the spread of infection, reduce the height of the epidemic
peak thus decreasing the pressure on health care facilities, and significantly reduce
morbidity and mortality of pandemic infections. Thus our main outcome measures
are the age specific attack rates and number of fatal cases.
The overall attack rates are summarized in Figure 2 and Figure 3. We can see that
by means of illness attack rate, the strategy E gives the best result, followed by
D,B,A and C in that order, whenever we start the vaccination campaign. In case
of an early start on day 1, all of the five strategies are effective with attack rates
between 1-4 %. As the delay in start of vaccination increases, the significance of our
choice of strategy becomes more apparent. We can advert the infection of 10 % of
the population by choosing strategy E instead of C if the campaign starts between
days 30 and 45. If vaccination starts on day 50, the attack rates will be between
21-29 %. For the sake of comparison we note that in the absence of a vaccination
campaign, R0 = 1.4 results in an a 42% attack rate.
The delay T in start of vaccination is a crucial factor on the final size of the pan-
demics: even for the best strategy, ten days delay can increase the overall attack
rate by up to 6% (see Figure 3).
Figure 4 shows the attack rates in the five age groups for the five strategies and
also for the case when there is no vaccination at all. Depending on which age group
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Figure 2. Overall attack rates of the five strategies for various
delays T in starting the vaccination campaign (A - Conventional,
B - Uniform, C - Elderly first, D - Children first, E - By contacts)
for R0 = 1.4. Without vaccination, the attack rate is 42%.
Figure 3. Overall illness attack rates of the five strategies plotted
versus the delay T (A - Conventional, B - Uniform, C - Elderly
first, D - Children first, E - By contacts) for R0 = 1.4. Without
vaccination, the attack rate is 42%.
we want to protect, we can choose different strategies. Since age groups peak at
different times, the delay in start of vaccination may also be a factor in choosing
our strategy: for example for T = 50 the strategy C, which gives priority to the
elder age group, protects them essentially to the same extent as any other strategy
(attack rates slightly over 10%), while there are large differences in the attack rates
for the age groups 0-9 and 10-19 years old. For T = 0 and T = 25 the strategy
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E protects the elder better with 0.5% and 3.2% attack rates versus the 1.4% and
5.4% attack rates that correspond to the strategy C among the elder age group,
despite the fact that in the strategy E they are the last to get the vaccine. This
very interesting result may seem counterintuitive, however some similar findings
have already been obtained for preseasonal vaccination in Medlock & Galvani 2009.
Furthermore, the public health implication of this phenomenon is that if the actual
policy is to protect a specific age group, then the best strategy depends also on
the delay in start of vaccination, therefore authorities must be able to adapt their
strategy as the pandemic evolves. Very high attack rates can be observed among
teenagers for strategies A,B and C.
Figure 4. Age specific attack rates of the five strategies in the
age groups 0-9, 10-19, 20-39, 40-64 and 65+ years old, represented
by the five columns, respectively, for various delays T in start of
the campaign: T = 0 (blue), T = 25 (red) and T = 50 (yellow)
for R0 = 1.4. The colours indicate the increases in the attack
rates for longer delays in start of the campaign. The strategies: A
- Conventional, B - Uniform, C - Elderly first, D - Children first,
E - By contacts, 0 - No vaccination.
The comparison of the strategies by means of mortality is depicted in Figure 5. The
relation between the strategies for this outcome measure is similar to the attack
rates: strategy E being the best and C the worst. However, we can observe a much
bigger difference between the best and the worst schedules: the overall mortality is
50% higher for the strategy C than for the strategy E for a late start in vaccination,
and six times higher for an early start. The reason of this huge difference is partly
that compared to the elderly, the recent H1N1 causes unusually high mortality
among children and young adults, who has the most contacts as well and prioritized
by strategy E. The age specific details can be seen in Figure 6.
The epidemic curves in the five age groups are plotted in Figure 7 for strategies
A and E with T = 25. Notice that age groups peak in different times, and for the
strategy A the teenagers are affected disproportionally by the epidemics.
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Figure 5. Overall mortality (number of deaths in a population of
100000) of the five strategies (A - Conventional, B - Uniform, C -
Elderly first, D - Children first, E - By contacts) for T = 0, T = 25
and T = 50 days delay in start of the vaccination campaign, using
the mortality pattern of the baseline scenario (sum of the products
of the age specific attack rates, case fatality rates and population
sizes), for R0 = 1.4. The colours indicate the increases in the attack
rates for longer delays in start of the campaign.
5. Sensitivity analysis
We performed a systematic analysis to reveal the sensitivity to several key param-
eters. Our results turned out to be very robust in the sense that modifying some
parameters do not change which strategy is the best if our outcome measure is
the overall attack rate. However, the mortality pattern is important to select our
strategy to minimize the number of fatal cases. Changing several parameters at the
same time, we did not observe any unexpected behaviour.
Basic reproduction number
We consider a less (R0 = 1.2) and a more severe (R0 = 1.6) situation, Figure 7 shows
the dependence of the attack rates on T . In the milder case, we can observe that for
the early start of vaccination for all five strategies the attack rates are below 1%,
the difference between the strategies shows only for delayed start, attack rates being
between 2-4%. Thus a 60% vaccination coverage is able to prevent a large outbreak
even if the campaign starts relatively late. Note that without vaccination, the attack
rate is 22.5%. In the more severe situation in the case of late start each strategy can
mitigate the pandemic only a little and there is not much difference between the
attack rates: about 50% for all strategies. In the absence of vaccination, the attack
rate is 55%, thus in this situation the vaccination campaigns are not effective. There
is a significant difference between the strategies if we start the campaign early, in
this case with strategy E we have only 5% attack rate, while for the worst strategy
C the attack rate is as high as 19% if T = 0. In the even more severe case R0 = 1.8,
for the early start the attack rates vary between 18 and 36%, strategy E being far
the best. However, for the late start the difference between the strategies mostly
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Figure 6. Epidemic curves (absolute numbers of infections) in
the age groups for strategies A (conventional) and E (by contacts),
when vaccination starts on day 25, in a population of 100 000 in
the baseline scenario (R0 = 1.4).
vanishes and the attack rates exceed 60%, being very close to the 64% attack rate
of the no vaccination case.
Vaccine efficacy
Monitoring the serological responses to influenza vaccines alone is not sufficient to
establish evidence that a vaccine is effective, because there has been no clear rela-
tionship shown between serological response to influenza vaccination and subsequent
morbidity and mortality. Vaccine effectiveness measures with clinical outcomes may
provide better estimate for the evaluation of how much protection the vaccine may
provide, however such estimates are not readily available at this stage of the vac-
cination campaign against pandemic influenza. Considering less effective (qi = 0.7
for i = 1, ...4 and q5 = 0.5), or more effective vaccine (qi = 0.9 for i = 1, ...4 and
q5 = 0.7) against infection (see Basta et al. 2008, CDC 2008) resulted in slightly
lower and higher attack rates, respectively, typically by 0.5-1.5%.
Reduction of infectiousness
Different scenarios were considered regarding the infectiousness of vaccinees. Taking
δ = 1 (no reduction in infectiousness) or δ = 0.5 (more significant reduction in
infectiousness) did not change much in the outcomes, the differences in the attack
rates were less than 1%, compared to the baseline scenario δ = 0.75. Assuming
that unsuccessful vaccination shortens the infectious period by one day in case of
infection, i.e. 1/µIV = 2, the attack rates are decreased by less than 1%.
Intensity of vaccination campaign
For the purposes of this study we assumed that 60% coverage can be reached in 90
days in the baseline scenario. In the sensitivity analysis, we compared the strategies
A and E with respect to the intensity and the length of the vaccination campaign,
adjusting the phases accordingly. Assuming that we complete the vaccination of 60%
of the population in 120 days (i.e. vaccine is administered to 0.5% of the population
daily), then the attack rates were at most 4% higher for the strategy E, and 6%
higher for the strategy A, depending on the delay in start of the campaign. A less
intensive campaign enlarged the differences between the strategies, which implies
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that choosing the best strategy is even more important if the vaccine availability or
the capacity of the health care system is limited.
We found another counterintuitive result regarding the strategy A: vaccinating 60%
in 120 days gives a worse outcome than vaccinating 45% in 90 days. The reason
behind this phenomenon is that if we adjust our phases to the given time intervals,
than in the first case the phases will be longer and the most important age groups
in the second phase receive the vaccine in such a delay that outweighs the benefits
of vaccinating more people, and vaccinations after day 90 has very limited effect on
the outcome.
A much less intensive campaign, vaccination of only 30% in 90 days resulted in
drastically higher overall attack rates, up to 12%, depending on the strategy and
the delay in start of the campaign. Strategy E is consistently the best option for a
less intensive campaign, having 5-6% smaller attack rate than strategy A for both
early and late start of the campaign.
For a very intensive campaign, when 80% coverage is reached within 90 days, the
attack rates are lower, for example for strategy E it is 17% for T = 50, 4% for
T = 25 and below 2% for T ≤ 16.
Mortality patterns
For the sake of comparison, we examined the outcomes of the strategies for a mor-
tality pattern which is somewhat different from what we see for A(H1N1)v, namely
the 1957 pandemic. Suggested by Serfling et al. 1967, we assumed that the fatality
rates for the five age groups per 100 000 cases have the proportions 0.1:0:0.1:1:4,
meaning that mortality is four times higher in the elderly, than in the age group
40-64 years old etc. We observed that in this case there is no significant difference
in the mortalities between the five strategies, since the vast majority of fatal cases
occurs in the elder age groups, where the five strategies resulted in similar attack
rates.
It is important to notice that in Figure 5 we overestimated the number of fatal cases
for strategy A, since then the high risk groups are vaccinated first in each age group
thus proportionally less high risk people will be infected than in the other strategies,
reducing the mortality. This factor of reduction is hard to determine (see Fleming
& Elliott 2006 ), since we need to estimate the fraction of high risk individuals in
each age group, and also their relative risk for a fatal outcome. Nevertheless, we can
see that the ratio of the attack rates for strategy E and strategy A is 0.3 for the
case of an early start, and 0.65 for a late start, thus to fully compensate the higher
attack rate, prioritizing high risk groups in strategy A must result in a significantly
lower mortality.
Time duration to develop immunity after vaccination
Ignoring the time duration 1/µW needed to develop immunity decreased the attack
rates significantly, in some cases by 8% even for the best strategy. This shows the
importance of incorporating this time period into our model, otherwise the attack
rates are seriously underestimated.
Applicability of the model
To illustrate the applicability of our approach, we fitted the model to the Hungarian
data of the first wave of A(H1N1)v. The epidemic curve was reconstructed using
the public reports of the National Center for Epidemiology (www.oek.hu). For the
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Figure 7. Overall attack rates plotted versus the delay T in start
of the vaccination campaign for the cases R0 = 1.2 and R0 =
1.6, for the five strategies (A - Conventional, B - Uniform, C -
Elderly first, D - Children first, E - By contacts). In the absence
of vaccination, the attack rate is 22.5% for R0 = 1.2 and 55% for
R0 = 1.6
Figure 8. Epidemic curve (thin curve with dots) in Hungary (pop-
ulation 10 million) and the fitted model (thick curve), taking into
account the reduced contact numbers during school holidays. Vac-
cinations started on day 29.
simulation, we fixed the epidemiological parameters as in Table 1, employed pub-
licly available vaccination data (www.jarvany.hu) and performed a grid search with
respect to the basic reproduction number and the reduction of contacts during hol-
idays to find the best fit by means of ordinary least square method. The result can
be seen on Figure 8, where day 1 corresponds to September 1 and R0 ≈ 1.3. The
immunizations started on day 29, but with very low intensity first. The intensity
increased only in a later phase of the outbreak. In Hungary, roughly 30% of the
population received the vaccine in a three months period. The decrease in cases
after day 50 is due to a one week national school holiday. Note that we included
this very preliminary figure solely for the sake of illustration, to demonstrate the
applicability of our model in a real life situation, a more comprehensive and thor-
ough epidemiological analysis of the Hungarian data is in progress, which is beyond
the scope of this study.
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6. Conclusions
We have extended an established age structured mathematical population model
of influenza transmission, incorporating the interplay between the vaccination cam-
paign and the dynamics of the outbreak. The model has allowed us to compare
various age specific scheduling strategies for the overall attack rate, age specific
attack rates and number of fatal cases. We found that if 60% coverage is targeted
within each age group, the best scheduling scheme E (i.e. prioritizing age groups ac-
cording to the number of social contacts) can reduce the overall attack rate by 5-10
% and mortality by up to 30% relative to the worst strategy, depending on the delay
in start of vaccination. Previous studies suggest that this can be further optimized
by allocating more vaccines to young age groups, however the scope of our study
was to examine the significance of the age specific timing in the schedule, without
changing the overall coverage for the age groups. Our results clearly demonstrate
that consideration of age specific transmission is paramount to vaccination schedule
planning.
Several mathematical models have been developed to evaluate age specific vaccina-
tion strategies and the impact of timing for influenza outbreaks (Matrajt & Longini
2010, Medlock et al. 2010, Mylius et al. 2008, Sypsa et al. 2009, Tuite et al. 2010).
They mostly focused on vaccine allocation (for example in Mylius et al. 2008 and
Matrajt & Longini 2010, all vaccines are administered at once), while our main
purpose was to explore the effect of temporal order of prioritizations. Generally,
recommendations depend on the progress of the epidemic. Mylius et al. 2008 and
Matrajt & Longini 2010 suggested prioritizing high risk groups if vaccine becomes
available in a later phase of the epidemic, while if available early, they suggested to
protect high-transmission groups. We have consistently found that the attack rates
are the lowest when high-transmission groups are prioritized. However, this is most
important when we start the vaccination early. For a late start and higher reproduc-
tion numbers, the differences between attack rates are much smaller. Thus, if the
attack rates are similar, protecting the most vulnerable first can be a better strategy
resulting lower mortality. Medlock et al. 2010 was led to a similar conclusion, hence
our findings are in accordance with previous results in the literature. However, our
conclusions can be viewed as a refinement of earlier results in the sense that in our
model vaccines are administered continuously, and using our methodology we can
easily compare the attack rates of various scheduling schemes for any delay in start
of the campaign and any daily vaccine uptake. We demonstrated that, besides allo-
cation, the scheduling of age groups itself can have a huge impact on the outcome
of the epidemic, especially when vaccine is available early and the reproduction
number is relatively low.
Since optimizing public health responses to this new pathogen requires difficult de-
cisions over short timelines, a significant advantage of our approach compared to
some other (stochastic, or agent based network) models in the literature is its rela-
tive simplicity. It can be easily reproduced by other researchers and adapted to the
situations of various countries where the availability of vaccine will be delayed, to
identify better strategies to mitigate the burden of the pandemic. Also, such strate-
gies can be translated into a realizable public health policy. Other real life concerns,
such as to protect the most vulnerable by early vaccination of high risk groups,
or vaccinating health care and emergency personnel, and constraints in vaccine
availability or the capacity of the health care system can be readily incorporated.
Furthermore, the uncertainties involved in the parameters were assessed through a
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sensitivity analysis to examine whether such variation results in markedly different
outcomes. The sensitivity analysis showed the robustness of our results. However,
the strategy of public health authorities must be adaptive (see Chowell et al. 2009
for a Mexican case study), especially when there is a race between the spread of
the infection and the vaccination campaign, and certain parameters are clarified
only during the outbreak. As the mortality pattern becomes clear as the pandemic
progresses, it might be necessary to switch to a different strategy to minimize the
number of fatal cases.
Finally, we wish to emphasize the utmost importance of the early start of the
vaccination campaign: ten days delay may cause a significant, up to 6 % increase in
the overall attack rate.
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